(BNTC) |
| 0 (0%) 05-29 15:05 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 12.90 |
| Resistance 1: | 11.97 |
| Pivot price: | 11.50 |
| Support 1: | 10.47 |
| Support 2: | 8.71 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | -0.930 |
| Book Value | 5.340 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -19.9 |
| Return on Equity (ttm) | -29.6 |
Company news
Thu, 28 May 2026
Benitec Biopharma (BNTC) director option grant benefits Suvretta-managed funds - Stock Titan
Thu, 28 May 2026
Benitec Biopharma (BNTC) director David Friedman files initial Form 3 - Stock Titan
Thu, 28 May 2026
Precision Trading with Benitec Biopharma Inc. (BNTC) Risk Zones - Stock Traders Daily
Mon, 25 May 2026
TD Cowen Maintains Benitec Biopharma(BNTC.US) With Buy Rating - 富途牛牛
Sun, 17 May 2026
Technical Reactions to BNTC Trends in Macro Strategies - Stock Traders Daily
Thu, 14 May 2026
Benitec Biopharma reports Q3 FY2026 net loss $11.9M, cash $184.8M; advances BB-301 clinical program - TradingView
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
